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bstract
Post-surgical surveillance of non-functioning pituitary adenoma (NFPA) is based on magnetic resonance imaging (MRI) at 3 or 6 months then 1
ear. When there is no adenomatous residue, annual surveillance is recommended for 5 years and then at 7, 10 and 15 years. In case of residue or
oubtful MRI, prolonged annual surveillance monitors any progression. Reintervention is indicated if complete residue resection is feasible, or for
ymptomatic optic pathway compression, to create a safety margin between the tumor and the optic pathways ahead of complementary radiation
herapy (RT), or in case of post-RT progression. In case of residue, unless the tumor displays elevated growth potential, it is usually recommended
o postpone RT until progression is manifest, as efficacy is comparable whether treatment is immediate or postponed. The efficacy of the various RT
echniques in terms of tumor volume control is likewise comparable. RT-induced hypopituitarism is frequent, whatever the technique. The choice
hus depends basically on residue characteristics: size, delineation, and proximity to neighboring radiation-sensitive structures. Reduced rates of
ascular complications and secondary brain tumor can be hoped for with one-dose or hypofractionated stereotactic RT, but there has been insufficient
ollow-up to provide evidence. Somatostatin analogs and dopaminergic agonists have yet to demonstrate sufficient efficacy. Temozolomide is an
ption in aggressive NFPA resistant to surgery and RT. 2015 Elsevier Masson SAS. All rights reserved.
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ésumé
Après chirurgie, la surveillance des adénomes hypophysaires non fonctionnels (AHNF) repose sur l’imagerie par résonance magnétique (IRM)
éalisée 3, voire 6 mois, puis un an après l’intervention chirurgicale. En l’absence de reliquat adénomateux, une surveillance annuelle est recom-
andée pendant 5 ans, puis 7, 10 et 15 ans après la chirurgie. En cas de reliquat ou d’image douteuse, une surveillance annuelle prolongée précisera
’évolutivité éventuelle de la lésion. Une seconde intervention chirurgicale est justifiée en cas de possibilité d’exérèse complète d’un reliquat, de
ompression symptomatique des voies optiques, afin de garder une distance de sécurité entre la tumeur et les voies optiques avant irradiation
omplémentaire ou en cas de progression tumorale après radiothérapie. En présence d’un reliquat, il est le plus souvent justifié (sauf si la tumeur
anifeste un potentiel de croissance élevé) de différer la radiothérapie au moment où ce reliquat évolue, son efficacité étant comparable que le
raitement soit réalisé d’emblée ou différé. L’efficacité des différentes techniques de radiothérapie sur le contrôle du volume tumoral est comparable.
’hypopituitarisme radio-induit est fréquent, quelle que soit la technique utilisée. Le choix dépendra donc essentiellement des caractéristiques
u reliquat (taille, limites, proximité des structures radio-sensibles avoisinantes). Avec les radiothérapies stéréotaxiques en dose unique ou hypo-
ractionnées, on espère une fréquence moindre des complications vasculaires et des rares tumeurs cérébrales secondaires ; mais le recul reste
nsuffisant. Les analogues de la somatostatine et les agonistes dopaminergiques n’ont pas fait la preuve jusqu’alors d’une efficacité suffisante. Le
émozolamide peut être discuté chez les patients présentant des AHNF agressifs après chirurgie et radiothérapie.
 2015 Elsevier Masson SAS. Tous droits réservés.
ots clés : Adénomes hypophysaires non fonctionnels ; Adénomes gonadotropes ; Adénomes hypophysaires silencieux ; Adénomes hypophysaires non
r
t
i
c
[
1
c
o
w
i
R
N
a
i
e
R
t
b
y
s
R
a
a
e
s
oécrétants ; Chirurgie hypophysaire ; Radiothérapie
Despite recent progress in neurosurgery, surgical treat-
ent of non-functioning pituitary macroadenoma (NFPA) often
chieves only partial tumor resection and recurrence is frequent
ithout adjuvant therapy [1–11] (Table 1).
.  Factors  for  recurrence  of  non-functioning  adenoma
Several studies have focused on factors for recurrence in
FPA, but were often retrospective, with small series and vari-
ble lengths and methods of follow-up. Criteria for recurrence
ere variable, sometimes failing to make the distinction between
rogression of postoperative residual tumor and true recurrence:
.e., new tumor onset after complete resection. However, there
ave been several recent meta-analyses [12,13] reporting higher
ecurrence rates in NFPA than in secreting adenoma. This has
aried little over the last 30 years [14,15].
.1.  Clinical  factors
The best identified recurrence factor is postoperative ade-
omatous residue (Table 1). In apparently complete resection
postoperative MRI interpreted as being normal), the recur-
ence risk is around 10–20% at 5 years and 30% at 10 years
2,5,8,10,16–18]. In case of postoperative tumoral residue,
ecurrence risk ranges from 25 to 40% at 5 years and exceeds
0% at 10 years, according to recent findings [2,5,7–11,16–18].
hen et al. [12], in a meta-analysis of 19 studies of accept-
ble quality (modern imaging, long follow-up), reported that the
ecurrence rate in patients without identifiable residue (n  = 371)
as 12%, with 96% remission at 5 years and 82% at 10 years; in
ase of postoperative adenomatous residue (n  = 600), the recur-
ence rate was 46%, with 56% progression-free survival at 5
ears and 40% at 10 years. Mean doubling time for adenomatous
esidue was 3.4 years.
s
>
s
wYoung age, gender and initial tumor size are non-systematic
ecurrence factors [4,11,19,20]. Apoplexy is not a guaran-
ee of definitive remission. Recurrence risk is increased in
nvasive tumor with extra-sellar progression (cavernous sinus,
livus), but this is also a risk factor for incomplete resection
4,10,21].
.2.  Histologic  factors
Progression may be bound to histologic type. Prognosis is
lassically poorer in silent corticotroph adenoma (SCA: 4–10%
f NFPAs). In Yamada et al.’s study [22], the cavernous sinus
as invaded in 85% of SCAs, compared to only 38% of non-
mmunoreactive adenomas and 11% of gonadotroph adenomas.
ecurrence rates in SCA are comparable to those in other
FPAs, but recurrence, when it occurs, is earlier and more
ggressive [23–26]. Prognosis in silent mixed GH-PRL adenoma
s likewise poorer [10].
As in other types of pituitary adenoma, tumor biomarker
xpression could contribute to determining prognosis [27–29].
esults regarding predictive value, however, have been con-
radictory [15,19–21,30]. Several reports found no correlation
etween Ki67 and/or p53 expression and recurrence risk at 10
ears [15,20]. The relation between Ki67 expression and inva-
ion is, moreover, variable [15]. However, in a recent study by
amirez et al., analyzing the expression of Ki67, PTTG, FGFR4
nd SST2 and 5 in 74 gonadotroph and non-immunoreactive
denomas, Ki67 (mean, 1.49) was the only biomarker with
xpression linked to tumor behavior [30]: on multivariate analy-
is, expression correlated with tumor diameter (>3 cm) and risk
f tumor recurrence (odds ratio: 1.4). Likewise Righi et al.,
tudying 75 NFPAs with a mean 6 years’ follow-up, found
3% Ki67 expression in 5% of tumors without recurrence ver-
us 30% in those with, while mitosis index and p53 expression
ere similar. Ki67 predicted recurrence with high specificity
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Table 1
Results of surgery in NFPA and recurrence risk according to postoperative tumor residue.
Authors Refs Total/without RT FU (years) Type of study Recurrence in
absence of residue
Recurrence in
case of residue
Turner et al. (1999) [1] 65/65 6.3 Retrospective 9/31 (20%) 12/34 (35%)
Woollons et al. (2000) [2] 72/22 5.3 Retrospective 2/11 (18%) 8/11 (73%)
Soto-Ares et al. (2002) [3] 51/51 5.6 Prospective 0/17 (0%) 13/34 (38%)
Greenman et al. (2003) [4] 122/108 4.2 Prospective 6/30 (20%) 41/78 (53%)
Ferrante et al. (2006) [5] 226/150 8.1 Retrospective 14/73 (19%) 45/77 (58%)
Dekkers et al. (2006) [6] 97/91 6 Retrospective 1/27 (4%) 9/64 (14%)
van den Bergh et al. (2007) [7] 122/46 8 Retrospective 1/18 (6%) 16/28 (57%)
Losa et al. (2008) [8] 436/355 4.5 Prospective PFS 5 years:
87.1%
PFS 5 years:
39.2%
O’Sullivan et al. (2009) [9] 126/126 5.7 Retrospective 0/26 (0%) 53/100 (53%)
Brochier et al. (2010) [10] 142/127 6.9 Retrospective 10/42 (24%) 46/85 (54%)
Reddy et al. (2011) [11] 144/144 6.1 Retrospective 2/29 (7%) 49/115 (43%)
Total 1603/1285 45/304 (15%) 292/626 (47%)
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tFS: progression-free survival.
89%) but poor sensitivity (54%), which suggests that new
hresholds need to be identified in these adenomas [21]. Finally,
everal recent studies related Ki67 expression to tumor dou-
ling time [19,31,32]. These findings suggest that Ki67 is not
redictive of recurrence risk but could be an effective index of
rogression risk in postoperative adenomatous residue. A new
denoma classification includes markers for radiologic and/or
istologic invasiveness, and for proliferation (Ki67, p53, mitosis
ndex: proliferation corresponding to 2 of the 3 being abnormal),
mproving the identification of residues liable to progress over
he long-term [29].
Other markers are under assessment. PTTG expression is
onstant and non-discriminative [30]. Expression of subtype
 and 5 somatostatin receptors is lower in recurrent adenoma
33]. Cyclin D1 is a proto-oncogene implicated in oncogenesis
nd pituitary invasion; recent studies, however, suggest its
xpression is not practically contributive to prognosis [34,35].
inally, other studies focused on the expression of angiogen-
sis markers, notably VEGF and FGFR4 receptors [30,36]. It
as very recently shown that endocan, a proteoglycan secreted
y endothelial cells, is expressed in pituitary adenoma: in a
eries of 107 cases at 8 years’ follow-up, expression was sig-
ificantly associated with mitosis index, tumor size and risk of
rogression [37]. The focus now is on identifying molecular
rognostic markers (ENC1, CLDN9, etc.), not yet available in
linical practice [38–41].
.  Postoperative  follow-up  of  NFPA
.1.  Imaging
Post-surgical radiologic monitoring is essential in NFPA,
ue to the frequent lack of clinical symptoms accompanying
rogression. Follow-up is preferably on MRI, pituitary CT scan
eing reserved to cases where MRI is contraindicated. Good
eproducibility is essential to the quality of follow-up, and can
deally be achieved by volume acquisition with 3D reconstruc-
ion; failing this, successive acquisitions should be made under
i
p
sdentical technical conditions, in the same reference plane (e.g.,
oronal slices perpendicular to the subcallosal plane). It is
mportant, for interpretation, to provide the radiologist with the
reoperative MRI scan and operative report, and a reference MRI
can taken 3 to 6 months after surgery. The imaging protocol
omprises thin (2–3 mm) sagittal T1, coronal T1 before and after
adolinium injection, coronal T2, or axial T1-weighted slices.
Immediate postoperative MRI is not systematic, but may be
rescribed for suspected postoperative complications or possi-
le early surgical revision in the days following primary surgery
42]. Otherwise, the first MRI will be performed at 3 or 6 months
3,43]. A 6-month interval reduces the rate of postoperative
emodeling artifacting interpretation, but a 3-month interval is to
e preferred in case of signs of large residue potentially threaten-
ng the optic pathways. Repeat MRI at 1 year is systematic. These
wo MRI scans serve as references for subsequent follow-up
3,43].
Precise interpretation of the postoperative reference MRI is
ssential, to determine whether residue, and hence a risk of pro-
ression, is present. When detectable adenomatous residue is
bsent or doubtful, MRI is repeated annually for 5 years and
hen at 7, 10 and 15 years. Systematic radiological follow-up
an then be stopped if there are no clinical signs, recurrence or
uspect images. Adenomatous residue is associated with recur-
ence, usually within 1–5 years [14] but sometimes later, more
han 10 years after primary surgery (20% of recurrences accord-
ng to Reddy et al. [11]). In case of adenomatous residue or
uspect image, MRI is repeated annually for 5 years and then
very 2–3 years in absence of progression, the schedule being
djusted on a case-by-case basis according to tumor size, dis-
ance from the optic pathways or doubt as to progression. Long
ntervals between check-ups entail a risk of loss to follow-up,
equiring particular vigilance (Fig. 1).
At each check-up, the new MRI should be compared against
he postoperative reference [6,15,42,44]: progressive residue
ncrease could be overlooked if the new MRI were to be com-
ared only with the previous one, since adenoma growth is often
low.
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Non-sytematic immediate post operative MRI
1st MRI 3 to 6 mon ths  posto perati vely
2nd MRI at 1 yea r
no identifiable residue
Annual MRI  for 5  years, then at 7, 
10 and15 years
Cease systematic surveillance in 
absence of clinical  signs, 
identifiable residue or  doubtful  MRI
adenomatous residue or doubtful 
MRI
Annual MRI  for 5  years, then 
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.2.  Ophthalmologic  follow-up
In case of preoperative ophthalmologic abnormality, a check-
p is made 3 months after surgery, exploring visual acuity,
isual field, fundus and possible diplopia. The examination
s repeated every 6 months until maximum improvement is
chieved, especially when initially severe visual disorder con-
raindicated driving; such contraindications are to be regularly
eassessed over follow-up. Surveillance may then be less fre-
uent. In the absence of any visual impairment on the first
ostoperative examination, follow-up can be stopped if there
s no suprasellar residue close to the optic pathways. If radi-
tion therapy (RT) is performed, prolonged annual follow-up
s necessary, especially after a hypofractionated or single-dose
egime, to screen for RT-related complications that may show
nset several years post-therapy.
.3.  Biologic  follow-up
Biological hormonal assessment, performed 3 months
ostoperatively, estimates recovery of hypopituitarism diag-
osed preoperatively and the definitive nature of post-surgical
ypopituitarism. Hormonal exploration is repeated to adapt
eplacement therapy if necessary in case of functional alarm
igns or increased volume of any residual tumor. Such deficits
re frequent after RT, requiring twice-yearly pituitary hormone
ssessment, as described above in the review by Raverot et al.
.  What  treatment  can  be  offered  for  residue  or
ecurrence?
.1.  Surgical  revisionBetween 30 and 48% of NFPAs undergo surgical revision on
 trans-sphenoid approach [8,9], either early for large residue,
r later during tumoral progression.
o
o
o
snon-functioning pituitary adenoma.
Revision surgery does not seem to enhance tumor control,
ith persistent residue in 72% of cases. Benefit is less than with
T. Efficacy in terms of visual recovery also seems to be less
han for primary surgery (58% versus 90%). Moreover, surgical
omplications are slightly more frequent [45].
Indications for revision surgery for recurrence of NFPA
hould take account of the primary surgery report and of residue
ize and location. Surgery is indicated for progressive residue
ccessible for complete resection, which can be limited by
nvasion of one or both cavernous sinuses; in case of persis-
ent or recurrent symptomatic optic pathway compression; to
btain anatomic conditions allowing stereotactic RT (3–5 mm)
afety margins between adenoma and optic pathways; or in case
f post-RT tumor progression. Primary surgery may also be
lanned in 2 steps: intrasellar resection, with a second step after
escent of the suprasellar contingent.
Remodeling of classical anatomic landmarks (sphenoidal
ostrum, sphenoid sinus septum) and impaired discrimina-
ion between different intrasellar tissues may hinder surgery.
ome authors recommend intraoperative neuronavigation in
uch cases, but this remains a matter of debate.
.2.  Radiation  therapy
After postoperative RT, recurrence risk in NFPA is consid-
rably reduced, 10-year progression-free survival being greater
han 90% in most series [7,10,12,45–50] (Table 2). A recent
eta-analysis [13] reported a relative risk of recurrence of 1.97
ithout versus with RT.
It is thus unsurprising that postoperative RT has been rec-
mmended as a complement to surgery for several decades,
lthough controversy remains as to indications and timing, due to
ssociated complications. Controversy persists mainly because
f the lack of randomized prospective efficacy studies for post-
perative RT in NFPA. Most studies have been retrospective and
bservational, and systematic analysis is hindered by numerous
election biases and study characteristics: varying definitions of
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Table 2
Efficacy of fractionated conformal RT on progression/recurrence risk in NFPA.
Authors Refs Number of patients FU (years) With/without RT % recurrence-free at 5 years % recurrence-free at 10 years
With RT Without RT With RT Without RT
Jaffrain-Rea et al. (1993) [46] 57 7.1 24/33 100% 70% 96% 55%
Gittoes et al. (1998) [48] 126 9 81/355 93% 68% 93% 47%
Woollons et al. (2000) [2] 72 5.3 50/22 72% 34% – –
Park et al. (2004) [49] 176 4.3 44/132 98% 85% 98% 50%
van den Bergh et al. (2007) [7] 122 8 76/46 95% 49% 95% 22%
Olsson et al. (2009) [50] 235 10 62/173 – – 94% 62%
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3rochier et al. (2010) [10] 142 6.9 15/1
ecurrence, varying rates of patients free of visible residue fol-
owing surgery, varying length of follow-up (often insufficient),
nd preferential selection of patients at high risk of recurrence
n RT groups. In a very few studies, RT was systematic after
FPA surgery, but most centers reserve RT to more aggressive
umors, large supra- or extra-sellar residual tumor or confirmed
ecurrence. Such biases systematically tend to weigh against RT
n efficacy studies.
.2.1.  Types  of  radiation  therapy
The first types of RT (known as “classical” or “conventional”)
sed a small number of beams, with 2D dosage study and rela-
ively wide (and often poorly delineated) margins. High total and
ractional radiation doses led to relatively high rates of severe
omplications such as cerebral necrosis and ophthalmologic
esion. Later, particle accelerators delivering high-energy X pho-
ons instead of cobalt improved depth rendering and reduced the
adiation field penumbra. Increasing the number of beams, with
otal doses of 45–50 Gy and fractionated doses of 1.8–2 Gy and
he introduction of simulators to locate target volumes accord-
ng to imaging data, with direct linkage to dose calculation,
rought further considerable improvements. The “conformal”
echnique uses 3D target location and dosimetry, and multi-slice
an-beam collimators improve targeting of complex volumes.
inally, increasing the number of non-coplanar beams and being
ble to modulate intensity further reduce irradiation of healthy
eighboring tissue.
Radiosurgery is 1-step RT. The objective is to superim-
ose target limits and the chosen reference isodose, so that
he dose diminishes rapidly beyond the target, optimizing spar-
ng of healthy adjacent structures. This requires an invasive
tereotactic frame, to achieve precise positioning within 1 mm,
 high-resolution imaging system, and 3D dosimetry. The
evices used are the Gamma-Knife (201 cobalt60 sources on a
emisphere) and the linear accelerator (LINAC). The marginal
ose is usually 13–16 Gy in NFPA. This type of RT is feasible
nly if the target volume is clearly visible, small (<2–3 cm on
he long axis) and sufficiently remote from the optic pathways
o ensure <8 Gy irradiation of the chiasm and optic nerves.Fractionated stereotactic RT associates the ballistic precision
nd multiple beam entries of radiosurgery to the principle of
ealthy tissue radioprotection by fractioning. The total dose is
5–50 Gy by 1.8–2 Gy fractions.
r
p
2100% 70% 91% 52%
CyberKnife is a miniaturized accelerator with a robotic
rm, enabling hypofractionated stereotactic RT (3–9 sessions,
epending on the team) with a non-invasive contention system
ased on the technical and dosimetric principles of radiosurgery.
Proton therapy is not widely available and thus little used for
FPA.
.2.2. Results  of  radiation  therapy
.2.2.1. Fractionated  conformal  radiation  therapy.  Many stud-
es now have demonstrated the efficacy of fractionated RT in
reventing postoperative recurrence of NFPA (Table 2). For sim-
licity’s sake, Table 2 presents only the more recent publications
1991–2010), analyzing recurrence risk with sufficient follow-
p, and including both patients receiving postoperative RT and
hose managed by surgery alone.
It emerges that almost all the reports show highly signifi-
ant benefit of RT for non-recurrence rates at 5 years (without
T, 66 ±  19%; with RT, 94 ±  9%) and 10 years (without RT,
2 ±  16%; with RT, 92 ±  6%). Global relapse fell about 3-fold:
21/986 without RT (32%) versus 55/468 with (12%).
Two factors bear on the benefit of RT: length of follow-up,
ccentuating the difference in recurrence even after 10 years;
nd postoperative residual tumor, in presence of which RT shows
ven clearer benefit, with mean global relapse falling from 62 to
7% [2,5,10]. Other factors may also influence efficacy, such as
umor type (oncocytic tumor being the most radioresistant [51])
r irradiation field area [52], but these findings have not been
ormally validated.
Late RT seems to be as effective in tumor control as imme-
iate postoperative RT [49].
.2.2.2. Fractionated  stereotactic  radiation  therapy.  Efficacy
tudies of fractionated stereotactic radiation therapy report a
maller number of patients, with mean follow-up usually not
xceeding 5 years [53–57] (Table 3). Results are generally
imilar to those of classic RT, with tumoral control achieved
n more than 95% of cases at 5 years.
.2.2.3. Radiosurgery.  Radiosurgery is usually postoperative,
eserved for small, well-defined residues remote from the optic
athways (Table 4).
Most studies involved smaller numbers of patients, with
.5–6.5 years’ follow-up [58–68]. Results were generally
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Table 3
Efficacy of fractionated stereotactic RT on recurrence risk in NFPA.
Authors Refs Number of patients Recurrence (%) Median FU (years) 5-year RFS %
Milker-Zabel et al. (2001) [53] 68a 5 3.2 93
Paek et al. (2005) [54] 65 2 2.5 98
Colin et al. (2005) [55] 110a 1 4 99
Minniti et al. (2006) [56] 91a 3 2.8 98
Schalin-Jäntti et al. (2010) [57] 20 0 4.5 100
RFS: recurrence-free survival.
a
s
9
9
a
t
b
T
s
3
a
(
r
c
a
b
t
s
c
3
3
i
(
I
q
r
[
R
i
e
a
o
p
b
c
T
E
A
W
S
P
I
P
W
W
M
L
P
H
L
S
M
R
tStudies including functioning tumors.
imilar to those of classic RT, with tumoral control achieved in
0–100% of cases at 5 years. Data for 512 patients managed in
 North American centers showed 95 and 85% tumoral control
t 5 and 10 years, respectively [69]. Efficacy was comparable
o that of first-line treatment [70]. A recent meta-analysis found
etter tumoral control in tumor volumes less than 4 ml [71].
here are no controlled studies comparing radiosurgery versus
urgery alone.
.2.2.4.  CyberKnife  radiotherapy.  Tumoral control was
chieved in 98% of cases in 100 patients at a mean 33 months
range: 18–118.5 months) after CyberKnife RT for NFPA
esidue with or without progression [72].
Wilson et al. [68], in a recent study, compared results in
onventional fractionated RT, LINAC stereotactic radiosurgery
nd fractionated stereotactic RT. Allowing for various inclusion
iases (historic series for conventional fractionated RT, smaller
umors remote from the optic pathways for stereotactic radio-
urgery, etc.) they concluded that efficacy in terms of tumoral
ontrol was comparable between these types of RT (Table 4).
2
b
2
able 4
fficacy of radiosurgery on recurrence risk in NFPA.
uthors Refs Number of patients 
owra and Stummer (2002) [58] 45 
heehan et al. (2002) [59] 42 
etrovich et al. (2003) [60] 56 
wai et al. (2005) [61] 31 
icozzi et al. (2005) [62]
ith Gamma-Knife 51 
ithout Gamma-Knife 68 
ingione et al. (2006) [63] 90 
iscák et al. (2007) [64] 79 
ollock et al. (2008) [65] 62 
öybye and Rähn (2009) [66] 168 
osa et al. (2011) [67] 23 
heehan et al. (2013) [69] 512 
ixed study
Wilson et al. (2012) [68]
RS (LINAC) 51 
FSRT (LINAC) 67 
FCRT 53 
FS: recurrence-free survival; FSRT: fractionated stereotactic radiation therapy; RS: ra
herapy.
a RFS at 3 years..2.3.  Complications  of  radiation  therapy
.2.3.1.  Fractionated  conformal  radiation  therapy.  Hypopitu-
tarism is the most frequent complication of fractionated RT
Table 5). Onset may be at several years, progressing over time.
t is pituitary and especially hypothalamic deficiency, thus fre-
uently associating moderate hyperprolactinemia. Frequency
anges between 50 and 80% in follow-up exceeding 10 years
45]: prolonged regular follow-up is thus required after RT.
educing total dose to <50 Gy and dose per fraction to 1.8 Gy,
ncreasing beam number and 3D dosimetry have succeeded in
liminating radionecrosis [73]. Ophthalmologic complications
re rare (<1%), and sometimes late [73], associated with baseline
ptic pathway involvement.
Radiation-induced cerebral tumor after conventional RT for
ituitary adenoma is a rare but well-established risk. It may
e astrocytoma [45,74], glioma or glioblastoma [47,73], sar-
oma [45,74,75] or meningioma [45,74] (observed in some cases
0 years post-RT). In a series of 426 adenomas treated by RT
etween 1962 and 1994, the risk was 2% at 10 years, 2.4% at
0 years and 8.5% at 30 years [74].
Recurrence (%) Median FU (years) 5-year RFS %
7 4.5 93a
2 2.5 NA
0 3 100a
13 93
ND 5 51
ND 5 90
8 3.75 NA
0 5 100
3 5.4 95
5 3.5 94
4 6.5
6,6 3 95
0 4.2 100
9 5.1 93
13 4.4 87
diosurgery; LINAC: linear accelerator; FCRT: fractionated conformal radiation
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Table 5
Efficacy and complications for the different types of RT.
Conventional/conformal Fractionated
stereotactic
CyberKnife LINAC Gamma-Knife
Tumoral control 5 years: 72–100%
10 years: 93–98%
20 years: 70–90%
93–100% 93–98% 93–98% 89.9–100%
Hypopituitarism with time
50–80% at >10 years
5–35% 0–20% 0–9.8% 7–40%
Ophthalmologic complications <1% <1% 0–1% <2% 0–13.7%
Secondary tumor 1.3–2% at 10 years
1.9–2.7% at 20 years
? ? ? Rare glioblastoma,
sarcoma
Radionecrosis ? Reported ?
Vascular Conventional: RR 1.5
to 4 (dose, female,
surgery)
Not reported Not reported Intracavernous carotid
stenosis, stroke
Intracavernous carotid
stenosis
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Cognitive disorders, varying from subject to subject, have
een reported in patients followed for pituitary adenoma, but
ith no clear demonstration of the involvement of RT [76] in
he absence of any prospective studies. The pathophysiology of
ognitive disorders is probably multifactorial: anatomic impact
f large adenoma, overlooked or poorly compensated hormone
eficits, surgical sequelae, etc. The impact if any of RT on quality
f life is controversial [77] and also seems to be multifactorial:
ge and gender, type of surgery, possible hypopituitarism and
reatment.
Ionizing radiation may trigger a reaction cascade in endothe-
ial cells and leukocytes (expression of adhesion molecules,
ytokines and chemokines, etc.), leading to a pro-thrombotic
tate and vascular inflammatory reaction. This post-RT vascular
nflammatory state may, in the medium- to long-term, induce or
ggravate atherosclerosis [78]. Hypopituitarism, whether or not
econdary to RT, may also increase vascular risk [79]. Stewart
t al. demonstrated in mouse that RT was an independent fac-
or for lesions to irradiated arteries, with possible synergy with
nown cardiovascular risk factors [80]. The first human stud-
es were prompted by excess post-RT mortality not accounted
or by progression of the adenoma or RT-induced tumor. Vas-
ular risk is elevated in female subjects and in case of pituitary
urgery preceding RT [81]. Stroke has also been associated with
lassical external (“conventional”) RT [73,79,81,82]. The spe-
ific technique may be implicated, notably the use of two lateral
eams, margin width, and use of 2D dosimetry. Vascular lesions
ave not been reported following fractionated stereotactic RT,
ut few studies reported such vascular complications precisely
83].
.2.3.2.  Radiosurgery.  In the short-term, headache (<5%), nau-
ea, asthenia and pain at the stereotactic frame anchorages have
een reported in Gamma-Knife and LINAC radiosurgery.
Following Gamma-Knife radiosurgery, the risk of visual
mpairment ranges, depending on the series, from 0 to 13.7%.
nset may be very early, within days, but is usually later, with a
eported maximum of 93 months. Several risk factors have been
dentified: history of conventional RT, iterative radiosurgery,
3
a
t
w? ? Trigeminal neuralgia
re-existing visual pathway involvement, multiple isocenters
84], large tumor volume [69] and, above all, <3–5 mm distance
rom the chiasm and >8 Gy [85] (or according to other authors
0 Gy [86]) irradiation planned for the chiasm. RT-induced
culomotor impairment has been reported with Gamma-Knife
84], sometimes being transient. Even so, the cranial nerves
assing through the cavernous sinus seem to be more radiore-
istant than the optic nerve or the chiasm [87]: 19–23 Gy were
elivered without clinically serious impact [88,89]. Systematic
-monthly ophthalmologic monitoring during the first 4 years
nd then annually for 10 years should be implemented. A rare
linical presentation of ocular neuromyotonia has been reported
ollowing Gamma-Knife RT [90].
Following Gamma-Knife RT, onset of hypopituitarism is not
lways screened for optimally and systematically. Follow-up
uration is variable and in many cases too short. For all these
easons, a reliable epidemiology for these complications is diffi-
ult to determine. In the literature, the incidence of RT-induced
ypopituitarism varies between 7 and 40%. Onset may be very
ate. Identified risk factors comprise target volume (>4 ml) [71],
esidue proximity to the pituitary gland and stalk, maximum
ose received by the pituitary gland >15 Gy and by the dis-
al infundibulum >17 Gy [69,91–93], no healthy pituitary gland
een on MRI [92], pre-existing partial hypopituitarism [93], and
revious RT [69].
Radionecrosis has not been reported following Gamma-Knife
T in NFPA, although there have been some few cases following
INAC radiosurgery (<3%).
Rare cases of trigeminal neuralgia and intracavernous internal
arotid thrombosis [94] have been reported with Gamma-Knife
nd LINAC. There are as yet insufficient data to assess the risk
f onset of cognitive disorders. Three cases of RT-induced tumor
ollowing Gamma-Knife treatment of a pituitary lesion have
een reported [95,96]..2.3.3.  Hypofractionated  stereotactic  RT  (CyberKnife).  Data
re as yet very preliminary for CyberKnife, although hypofrac-
ionation should significantly reduce side effects. Treatment is
ell-tolerated ophthalmologically if the chiasm and/or optic
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tude for regular prolonged surveillance, any hypopituitarism,
and the feasibility of and experience with secondary therapiesC. Cortet-Rudelli et al. / Annales
erves do not receive too much radiation. A single case
f transient oculomotor involvement has been reported [97].
ypopituitarism prevalence has been estimated at 0 to 20%.
here have been no reports of radionecrosis or secondary tumor,
ut follow-up has been short.
3.2.3.3.1.  To  sum  up.  The efficacy of postoperative RT in
FPA now seems undeniable, whatever the technique Late RT
eems to be as effective in tumor control as immediate postop-
rative RT. Benefit emerges more clearly with longer follow-up
nd for larger postoperative residue. Benefit is, however, to be
eighed against known side effects, notably RT-induced hypopi-
uitarism and secondary brain tumor. The impact of the various
ypes of RT on cognitive function and quality of life remains
ery poorly elucidated.
Most experts now agree that immediate postoperative RT is
ot indicated after complete tumor resection, as the recurrence
isk is low. Treatment can be postponed without loss of efficacy,
ut regular radiological surveillance should be maintained over
 period of many years.
In the absence of significant and, especially, invasive tumor
esidue, indications for RT should take account of risk factors
or regrowth, patient age and history, and any hypopituitarism.
n most cases, regular surveillance can be the first-line attitude,
ith treatment postponed until the residue shows progression
nd/or becomes threatening. RT is indicated if the tumor shows
levated growth potential and the risk of hypopituitarism is not
 major problem.
The efficacy of the various types of RT is comparable in terms
f tumoral control (Table 5) and the choice depends on the size,
imits and location of the residue with respect to neighboring
eural structures and on the center’s particular experience with
he various techniques. Before indicating single-dose RT, the
isk/benefit ratio needs to be assessed: there is no point in trying
o minimize complications by adopting a low-dose attitude if
his would lead to insufficient tumoral control.
.3.  Medical  treatment
Gn-RH agonists and antagonists have been proved ineffective
or reducing NFPA volume.
The discovery of dopaminergic receptors (especially type
2 [98,99] [100], but also D4) and somatostatin receptors
SST3 and SST2) [30,101] within NFPA, plus in vitro findings,
ave led to dopaminergic agonists and somatostatin analogs
eing deployed in NFPA. Series have been small and hetero-
eneous (inclusion criteria, treatment being administered in
rst-line or not, systematically after surgery or only in case
f recurrence, efficacy assessment criteria, presence of visual
igns, comparison against control group, etc.). No long-term
rospective studies against placebo have been performed. The
opaminergic agonists (bromocriptine, quinagolide and espe-
ially cabergoline), doses (up to 3 mg/day for cabergoline) and
reatment durations (1 to 93 months) all varied. It is difficult
o assess efficacy in terms of tumor volume in the absence
f any controlled studies. Volume reduction has been reported
98,100,102] and seems to be associated with D2 receptor
xpression (especially the short isoform) within the tumor.
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reatment sometimes leads to improvement in ophthalmologic
isorders, even if there is no significant reduction in tumoral
olume.
The somatostatin analogs and treatment duration (1–37
onths) again varied between studies [103]. Volume reduction
as reported in a small percentage of cases. Treatment may
rovide rapid relief of headache and visual field defect, once
gain possibly independently of an antitumoral action. Somato-
tatin receptor scintigraphy is non-predictive of analog effects
103,104]. There are no data regarding tumor progression after
reatment termination. An association of dopaminergic agonists
nd somatostatin analogs was tried, without improving effi-
acy [105]. The interest of pasireotide, a novel somatostatin
nalog with affinity for all SSTs except subtype 4, was sug-
ested in an in vitro study [106]; in vivo data are presently
acking. In conclusion, none of these medical therapies has
hown sufficiently reliable significant efficacy in terms of tumor
olume to be recommended in case of failure of surgery
n NFPA.
Temozolomide is an oral alkylating agent that is effec-
ive in pituitary carcinoma and aggressive adenoma (mainly
actotroph or corticotroph) [107]. Low tumoral expression of O6-
ethylguanine DNA methyltransferase (MGMT) is associated
ith good temozolomide response. A recent study [31] asso-
iated lower MGMT expression in recurrent than non-recurrent
FPA, suggesting a possible interest of temozolomide in aggres-
ive NFPA.
Recent reports suggest that Raf/MEK/ERK and PI3K/Akt/
TOR (mammalian  target  of  rapamycin) pathway regulation
bnormalities are implicated in cell proliferation in pituitary
denoma [108]. The action of rapamycin is down-regulated by
kt phosphorylation, which in turn is reduced by SST2 stimu-
ation. Thus, an in vitro study showed rapamycin sensitization
f adenomatous cells by addition of octreotide [109], suggest-
ng a theoretic interest of concomitant somatostatin analog and
TOR pathway inhibitor treatment.
.  Conclusion
Post-surgically, if there is no identifiable adenomatous
esidue or in case of doubtful image, prolonged regular surveil-
ance should be implemented, as the risk of complications
ollowing secondary treatment (surgery or radiotherapy) is
reater than that of recurrence and/or complications related to
ecurrence.
In case of adenomatous residue: morphology (size, lim-
ts, distance from optic pathways, cavernous sinus invasion),
natomopathology (immunohistochemistry, Ki67, p53, mitosis
ndex), residue progression, patient age and history and apti-n the center are factors in decision-making, in agreement with
he patient, in a multidisciplinary team meeting involving the
euroradiologist, neurosurgeon, radiotherapist and endocrinol-
gist.
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